Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Latent TB Infection for Jailed Persons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria for this study will be San Francisco Jail inmates, age 18 or older (the jail does not house juveniles) having evidence of M. tuberculosis infection by positive tuberculin skin test (a documented reactive tuberculin skin test to 0.1 mL containing 5 Tuberculin Units) who meet current national criteria for therapy for tuberculosis infection and can provide informed consent.~Exclusion Criteria:~* Ineligible for either therapy regimen for any of the following reasons:~  1. history of treatment-limiting reaction to isoniazid or rifamycins;~ 2. pregnancy or breast feeding;~ 3. active tuberculosis;~ 4. an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 times the upper limit of normal;~ 5. bilirubin \>2 times the upper limit of normal;~ 6. platelets \<150 K/mm3;~ 7. taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs);~* Unable to communicate in English or Spanish;~* Unable or unwilling to provide informed consent;~* Not in the routine level of jail security for any reason (housed in special security areas);~* Any condition that, in the best judgment of the investigator, would pose a risk to the subject during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- B (Type: ACTIVE_COMPARATOR): isoniazid (INH) (900 mg orally) given twice weekly for 9 months
- A (Type: ACTIVE_COMPARATOR): rifampin (600 mg orally) given daily for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).